Back to top
more

Twist Bioscience (TWST)

(Delayed Data from NSDQ)

$27.52 USD

27.52
2,460,723

-2.69 (-8.90%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $28.35 +0.83 (3.02%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of +12.96% and +0.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of -17.86% and 0.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics

by Zacks Equity Research

Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics are part of the Zacks top Analyst Blog

Ekta Bagri headshot

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

by Ekta Bagri

Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.

Zacks Equity Research

Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?

by Zacks Equity Research

Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Avantor Stock Declines Despite Q4 Earnings Beat, Margins Expand

by Zacks Equity Research

Despite AVTR's stability in proprietary chemicals and specialty procurement sales, it reports an overall soft fourth-quarter performance.

Zacks Equity Research

Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

BD Stock Falls in Pre-Market Despite Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

Zacks Equity Research

Company News for Feb 4, 2025

by Zacks Equity Research

Companies In The News Are: ARLP, TSN, IDXX, TWST.

Zacks Equity Research

Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 14.52% and 2.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy

by Zacks Equity Research

Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alvotech (ALVO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

Zacks Equity Research

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Agios Pharmaceuticals (AGIO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

Zacks Equity Research

Company News for Nov 19, 2024

by Zacks Equity Research

Companies In The News Are: TWST, CVS, OKLO, HSIC.

Zacks Equity Research

Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 19.18% and 2.59%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cyclo Therapeutics (CYTH) delivered earnings and revenue surprises of -52.94% and 24.52%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -23.33% and 7.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of 5.26% and 8.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vericel (VCEL) delivered earnings and revenue surprises of 60% and 4.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adma Biologics (ADMA) Soars 18.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of -8.86% and 5.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Zacks Equity Research

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.